ClinicalTrials.gg
Not yet recruitingNCT07445360Updated May 11, 2026

Circumferential Pulmonary Venous Isolation Combined With Bachmann Bundle Modification Versus Circumferential Pulmonary Venous Isolation for Persistent Atrial Fibrillation

An interventional study of Traditional pulmonary vein isolation (PVI) ablation and Bachmann bundle modification in Persistent Atrial Fibrillation, sponsored by Shenyang Northern Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Shenyang Northern Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a prospective, randomized controlled, single-blind, multicenter study design. To evaluate the safety and efficacy of traditional pulmonary vein isolation (PVI) alone and PVI combined with Bachmann bundle ablation on persistent atrial fibrillation.

According to the treatment strategy, they were divided into two groups. Control group: circumferential PVI alone group (CPVI). Experimental group: CPVI combined with Bachmann bundle ablation group (CPVI-BBM).

Read the detailed description

Catheter ablation enhances the likelihood of maintaining sinus rhythm in patients with atrial fibrillation (AF); however, the procedural success rate remains suboptimal in individuals with persistent AF. Research indicates that the Bachmann bundle plays a significant role in the initiation and maintenance of AF. In a study utilizing a porcine model, Schwartzman et al. demonstrated that ablation at various sites within the right atrial septum-specifically, the fossa ovalis, the crista terminalis of the right atrium, and the coronary sinus ostium-can effectively disrupt left-right atrial conduction. This disruption occurs without impairing the conduction function of the atrioventricular node or inducing other atrial arrhythmias, although it does result in the cessation of electrical and mechanical activity in the left atrium. Kumagai et al. conducted radiofrequency ablation on the central portion of the Bachmann bundle on the epicardial surface of the canine heart, successfully blocking interatrial conduction and terminating AF. Electrophysiological mapping revealed an absence of activation entering the right atrium from the Bachmann bundle, and no evidence of the Bachmann bundle's involvement in the formation of a reentry loop was observed.This study seeks to examine the safety, efficacy, and long-term outcomes associated with the integration of circumferential pulmonary vein isolation (CPVI) and Bachmann bundle ablation in the management of persistent atrial fibrillation. Participants were allocated into two distinct groups based on the treatment strategy: the control group, which received pulmonary vein isolation alone (CPVI), and the experimental group, which underwent a combination of pulmonary vein isolation and Bachmann bundle ablation (CPVI-BBM).

02

Conditions studied

  • Persistent Atrial Fibrillation

Browse trials for

Keywords

  • Circumferential pulmonary venous isolation
  • Bachmann bundle modification
03

In context

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

This study's planned enrollment of 320 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

Shenyang Northern Hospital is the lead sponsor of 42 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects≥ 18 years old and ≤ 75 years old;
  2. the subject was diagnosed with persistent atrial fibrillation (duration of ≥6 months and ≤ 3 years);
  3. Able to understand the purpose of the trial, voluntarily participate in this study, the subject or his legal representative signed the form, and was willing to complete the follow-up according to the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Previous atrial fibrillation catheter ablation therapy, left atrial appendage closure or atrial fibrillation surgery;
  2. atrial fibrillation secondary to electrolyte imbalances, thyroid disease or other reversible disease, or non-cardiac causes;
  3. Left atrial or left atrial appendage thrombus (confirmed by esophageal ultrasound or CT examination);
  4. Patients with pulmonary vein stenosis or pulmonary vein stents implanted;
  5. Have had atrial septal repair or atrial myxoma;
  6. Severe structural heart disease (such as moderate to severe mitral regurgitation, dilated cardiomyopathy, hypertrophic cardiomyopathy, severe heart valve disease);
  7. Cardiac ultrasound showed that the diameter of the left atrium was ≥50mm
  8. New York College of Cardiology () cardiac function grades III and IV; \<40%;
  9. Those with cerebrovascular diseases (including stroke, ) in the past 3 months;
  10. Those who have had cardiovascular events in the past 3 months (including acute myocardial infarction, coronary intervention or heart bypass);
  11. surgery, prosthetic valve replacement or repair, atrial or ventriculotomy;
  12. Those with acute or severe systemic infection;
  13. Combined with severe liver and kidney insufficiency ( or ALT≥ 3 times the ; SCr>3.5mg/dl or Ccr\<30ml/min);
  14. Those with obvious bleeding tendency and hematologic diseases, or to anticoagulation;
  15. Patients with malignant tumors and end-stage diseases with a of \< 12 months; After chemotherapy or radiotherapy for malignant tumors;
  16. The subject is a female who is pregnant or lactating or cannot use during the trial;
  17. The subject has participated in clinical trials of other drugs or devices during the same period;
  18. Abnormalities or diseases that, in the opinion of the investigator, should be excluded from the scope of enrollment in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    CPVI-BBM

    Annular pulmonary vein electrical isolation combined with Bachmann bundle modification (CPVI-BBM)

    Procedure: Traditional pulmonary vein isolation (PVI) ablation · Procedure: Bachmann bundle modification

  • Active comparator
    CPVI

    Circumferential pulmonary venous isolation (CPVI)

    Procedure: Traditional pulmonary vein isolation (PVI) ablation

Interventions

  • ProcedureTraditional pulmonary vein isolation (PVI) ablation

    Traditional pulmonary vein isolation (PVI) ablation

  • ProcedureBachmann bundle modification

    Bachmann bundle modification

06

What researchers measure

Primary outcomes

  1. Sinus rhythm maintenance rate after ablation in the CPVI group and CPVI-BBM group at 1 year.

    Time frame: 1year

Secondary outcomes

  1. Immediate success rate of surgery

    Time frame: Intra-procedure

  2. Direct termination rate of intraoperative atrial fibrillation

    Time frame: Intra-procedure

  3. The number of cardioversions

    Time frame: Intra-procedure

  4. Total operative time (defined as the total time from the first femoral venous puncture to the final catheter removal)

    Time frame: Total operative time

  5. Left atrial operation time (i.e., the time from the time when the ablation catheter enters the left atrium to the time it is evacuated from the left atrium)

    Time frame: Left atrial operation time

  6. Ablation time, including total ablation time, CPVI ablation time, and BBM ablation time

    Time frame: Ablation time

  7. X-ray exposure time

    X-ray exposure time, including total exposure time, CPVI exposure time, and BBM exposure time

    Time frame: X-ray exposure time

  8. X-ray exposure dose

    X-ray exposure dose, including total exposure dose, CPVI exposure dose, and BBM exposure dose

    Time frame: intra-procedure

  9. The area and volume of the left atrium

    Calculate the area and volume of the left atrium in preparation for cardiac radiofrequency ablation

    Time frame: intra-procedure

  10. The area of double ring vein isolation after catheter ablation, and the proportion of the area of the pulmonary vein isolation area to the left atrial surface area

    Determine the area of double ring vein isolation following catheter ablation, as well as the ratio of the pulmonary vein isolation area to the total surface area of the left atrium.

    Time frame: Intra-procedure

  11. Whether and to what extent the atrial appendage potential is delayed under postoperative sinus rhythm

    Time frame: Intra-procedure

  12. Record whether to give stromal mapping ablation under sinus law; whether there is a combination of atrial prematurity/atrial tachycardia and ablation site; whether other linear ablation/alcohol ablation is given and the ablation site

    Time frame: Intra-procedure

  13. Early atrial fibrillation recurrence was detected by ambulatory ECG during the 3-month follow-up period after surgery; recurrence of atrial fibrillation, atrial flutter and other atrial arrhythmias during 1 and 3 years of follow-up after surgery

    Time frame: 3 month, 1 year and 3 years of follow-up after surgery

  14. Intraoperative and postoperative complication rates

    Intraoperative and postoperative complication rates, complications include: atrial esophageal fistula, pulmonary vein stenosis, cardiac tamponade/perforation, death, phrenic nerve palsy, myocardial infarction, pericarditis (pericardial effusion leading to hemodynamic damage or requiring pericardiocentesis; prolonged hospital stay for more than 48 hours; Requires hospitalization; post-ablation effusion lasting more than 30 days), stroke or transient ischemic attack (TIA), vagus nerve injury, severe vascular access complications.

    Time frame: From surgery to 3 months after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Teuwen CP, Does LJMEV, Kik C, Mouws EMJP, Lanters EAH, Knops P, Taverne YJHJ, Bogers AJJC, de Groot NMS. Sinus Rhythm Conduction Properties across Bachmann's Bundle: Impact of Underlying Heart Disease and Atrial Fibrillation. J Clin Med. 2020 Jun 16;9(6):1875. doi: 10.3390/jcm9061875. PubMed 32560096 ↗
  • van Staveren LN, van der Does WFB, Heida A, Taverne YJHJ, Bogers AJJC, de Groot NMS. AF Inducibility Is Related to Conduction Abnormalities at Bachmann's Bundle. J Clin Med. 2021 Nov 26;10(23):5536. doi: 10.3390/jcm10235536. PubMed 34884237 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Dec 2028, 31 months later.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 31 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2026
First posted
Mar 3, 2026
StartEst.
May 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07445360
Lead sponsor
Shenyang Northern Hospital
Responsible party
Wang Zulu (Director, clinical professor, Shenyang Northern Hospital) — Principal investigator
First posted
Mar 3, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 11, 2026

Study contacts

Ming Liang, PhD
Contact
lming000919@sina.com
+86-17790991573

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion